ArticleEndocrinology and metabolism (Seoul, Korea)2026
Ultrasound-Derived Fat Fraction and Metabolic Parameters in Predicting Panvascular Disease Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients: A Prospective Study.
Article in Endocrinology and metabolism (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgruoundPatients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at increased risk of panvascular disease (PD). Noninvasive markers for early risk stratification are needed. We evaluated whether ultrasound-derived fat fraction (UDFF) improves the prediction of PD occurrence in MASLD patients.
methodsIn this prospective cohort, 525 adults with MASLD were enrolled between October 2022 and December 2023 and followed for 6 months for PD occurrence. Baseline UDFF and clinical/metabolic variables were collected. Multivariable logistic regression analyses reported standardized coefficients (per-standard deviation [SD] β) and odds ratios (ORs) per 1-SD (OR). A decision tree model was constructed to explore differences across metabolic subgroups, including obesity, hypertension, diabetes, and multiple metabolic abnormalities. Discriminative performance was compared using the area under the curve (AUC; DeLong test).
resultsBody mass index (BMI), systolic blood pressure (SBP), homeostasis model assessment of insulin resistance (HOMA-IR), and UDFF were each associated with increased PD risk. In the multivariable model, the strongest standardized effects were observed for UDFF (β=3.28; OR, 2.10; 95% confidence interval [CI], 1.45 to 2.75) and BMI (β=1.87; OR, 1.68; 95% CI, 1.25 to 2.34), followed by SBP (β=1.33; OR, 1.15; 95% CI, 1.03 to 1.26). HOMA-IR (β=0.96; OR, 1.65; 95% CI, 1.30 to 2.15), age (β=0.56; OR, 1.06; 95% CI, 1.01 to 1.12), and liver stiffness measurement (β=0.14; OR, 1.03; 95% CI, 1.01 to 1.07) also showed smaller but significant associations. The decision tree model reflected similar patterns and achieved higher discrimination than logistic regression (AUC 0.85 vs. 0.80, P<0.05).
conclusionUDFF is a key predictor of PD risk in MASLD patients, underscoring the importance of risk stratification for early intervention and personalized management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.